Wolfson Molecular Imaging Centre, 27 Palatine Road, Withington, Manchester M20 3LJ, UK.
Nat Rev Urol. 2013 Apr;10(4):206-18. doi: 10.1038/nrurol.2013.24. Epub 2013 Feb 26.
Urine is an ideal body fluid for the detection of protein markers produced by urological cancers as it can be sampled noninvasively and contains secreted and directly shed proteins from the prostate, bladder and kidney. Major challenges of working with urine include high inter-individual and intra-individual variability, low protein concentration, the presence of salts and the dynamic range of protein expression. Despite these challenges, significant progress is being made using modern proteomic methods to identify and characterize protein-based markers for urological cancers. The development of robust, easy-to-use clinical tests based on novel biomarkers has the potential to impact upon diagnosis, prognosis and monitoring and could revolutionize the treatment and management of these cancers.
尿液是检测尿路上皮癌产生的蛋白标志物的理想体液,因为它可以非侵入性采样,并且包含来自前列腺、膀胱和肾脏的分泌和直接脱落的蛋白。尿液分析面临的主要挑战包括个体间和个体内的变异性大、蛋白浓度低、盐的存在以及蛋白表达的动态范围。尽管存在这些挑战,但是使用现代蛋白质组学方法来鉴定和表征尿路上皮癌的基于蛋白的标志物方面正在取得显著进展。基于新型生物标志物的稳健、易于使用的临床检测方法的开发有可能影响诊断、预后和监测,并可能彻底改变这些癌症的治疗和管理。